Structural basis of HIV-1 resistance to AZT by excision

Nature Structural and Molecular Biology

Volumn 17, Issue 10, 2010, Pages 1202-1209

  Tu, Xiongying ^a,b   Das, Kalyan ^a,b   Han, Qianwei ^b   Bauman, Joseph D ^a,b   Clark, Arthur D ^a,b   Hou, Xiaorong ^b   Frenkel, Yulia V ^a,b   Gaffney, Barbara L ^b   Jones, Roger A ^b   Boyer, Paul L ^c   Hughes, Stephen H ^c   Sarafianos, Stefan G ^a,b,d   Arnold, Eddy ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOUBLE STRANDED DNA; FUNGAL ENZYME; MUTANT PROTEIN; PYROPHOSPHATE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DNA SYNTHESIS; ENZYME BINDING; ENZYME STRUCTURE; EXCISION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS MUTATION; WILD TYPE;

ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DEOXYRIBONUCLEOTIDES; DIDEOXYNUCLEOTIDES; DNA, VIRAL; DRUG DESIGN; DRUG RESISTANCE, VIRAL; GENES, REV; HIV REVERSE TRANSCRIPTASE; HIV-1; MODELS, MOLECULAR; MUTATION, MISSENSE; POINT MUTATION; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMINE NUCLEOTIDES; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77957797787     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1908     Document Type: Article

References (60)

1. Fauci, A.S. 25 years of HIV/AIDS science: reaching the poor with research advances. Cell 131, 429-432 (2007).
2. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. & Steitz, T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790 (1992).
3. Jacobo-Molina, A. et al. Crystal structure of human immunodefciency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90, 6320-6324 (1993).
4. Huang, H., Chopra, R., Verdine, G.L. & Harrison, S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282, 1669-1675 (1998).
5. Sarafanos, S.G. et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc. Natl. Acad. Sci. USA 96, 10027-10032 (1999).
6. Das, K. et al. Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J. Biol. Chem. 284, 35092-35100 (2009).
7. Larder, B.A. & Kemp, S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-1158 (1989).
8. Arion, D., Kaushik, N., McCormick, S., Borkow, G. & Parniak, M.A. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37, 15908-15917 (1998).
9. Meyer, P.R., Matsuura, S.E., So, A.G. & Scott, W.A. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95, 13471-13476 (1998).
10. Meyer, P.R., Matsuura, S.E., Mian, A.M., So, A.G. & Scott, W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4, 35-43 (1999).
11. Boyer, P.L., Sarafanos, S.G., Arnold, E. & Hughes, S.H. Selective excision of AZTMP by drug-resistant human immunodefciency virus reverse transcriptase. J. Virol. 75, 4832-4842 (2001).
12. Jeeninga, R.E., Keulen, W., Boucher, C., Sanders, R.W. & Berkhout, B. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. Virology 283, 294-305 (2001).
13. Mas, A. et al. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J. 19, 5752-5761 (2000).
14. Boyer, P.L., Sarafanos, S.G., Arnold, E. & Hughes, S.H. Nucleoside analog resistance caused by insertions in the fngers of human immunodefciency virus type 1 reverse transcriptase involves ATP-mediated excision. J. Virol. 76, 9143-9151 (2002).
15. Meyer, P.R., Lennerstrand, J., Matsuura, S.E., Larder, B.A. & Scott, W.A. Effects of dipeptide insertions between codons 69 and 70 of human immunodefciency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J. Virol. 77, 3871-3877 (2003).
16. Meyer, P.R. et al. Relationship between 3′-azido-3′- deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodefciency virus type 1 reverse transcriptase. J. Virol. 77, 6127-6137 (2003).
17. Sluis-Cremer, N. et al. Molecular mechanism by which the K70E mutation in human immunodefciency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 51, 48-53 (2007).
18. Dharmasena, S., Pongracz, Z., Arnold, E., Sarafanos, S.G. & Parniak, M.A. 3′-Azido-3′-deoxythymidine-(5′)-tetraphospho-(5′)- adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase. Biochemistry 46, 828-836 (2007).
19. Han, Q., Gaffney, B.L. & Jones, R.A. One-fask synthesis of dinucleoside tetra-and pentaphosphates. Org. Lett. 8, 2075-2077 (2006).
20. Sarafanos, S.G. et al. Structures of HIV-1 reverse transcriptase with pre-and post-translocation AZTMP-terminated DNA. EMBO J. 21, 6614-6624 (2002).
21. Carfí, A., Smith, C.A., Smolak, P.J., McGrew, J. & Wiley, D.C. Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus. Proc. Natl. Acad. Sci. USA 96, 12379-12383 (1999).
22. Kleywegt, G.J. Use of non-crystallographic symmetry in protein structure refnement. Acta Crystallogr. D Biol. Crystallogr. 52, 842-857 (1996).
23. Carroll, S.S. et al. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry 33, 2113-2120 (1994).
24. Kerr, S.G. & Anderson, K.S. Pre-steady-state kinetic characterization of wild type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodefciency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry 36, 14064-14070 (1997).
25. Krebs, R., Immendorfer, U., Thrall, S.H., Wohrl, B.M. & Goody, R.S. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry 36, 10292-10300 (1997).
26. Hsiou, Y. et al. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4, 853-860 (1996).
27. Ueno, T. & Mitsuya, H. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 36, 1092-1099 (1997).
28. Deval, J. et al. The molecular mechanism of multidrug resistance by the Q151M human immunodefciency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J. Biol. Chem. 277, 42097-42104 (2002).
29. Sluis-Cremer, N. et al. The 3′-azido group is not the primary determinant of 3′-azido-3′-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J. Biol. Chem. 280, 29047-29052 (2005).
30. Meyer, P.R., Smith, A.J., Matsuura, S.E. & Scott, W.A. Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodefciency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants. Antimicrob. Agents Chemother. 50, 3607-3614 (2006).
31. Ray, A.S. et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 42, 8831-8841 (2003).
32. Selmi, B. et al. The Y181C substitution in 3′-azido-3′- deoxythymidine-resistant human immunodefciency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3′-azido-3′- deoxythymidine 5′-monophosphate-terminated primer. J. Biol. Chem. 278, 40464-40472 (2003).
33. White, K.L. et al. Molecular mechanisms of tenofovir resistance conferred by human immunodefciency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob. Agents Chemother. 48, 992-1003 (2004).
34. Boyer, P.L., Imamichi, T., Sarafanos, S.G., Arnold, E. & Hughes, S.H. Effects of the Delta67 complex of mutations in human immunodefciency virus type 1 reverse transcriptase on nucleoside analog excision. J. Virol. 78, 9987-9997 (2004).
35. Hooker, D.J. et al. An in vivo mutation from leucine to tryptophan at position 210 in human immunodefciency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J. Virol. 70, 8010-8018 (1996).
36. Harrigan, P.R. et al. Signifcance of amino acid variation at human immunodefciency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70, 5930-5934 (1996).
37. Romano, L. et al. Broad nucleoside-analogue resistance implications for human immunodefciency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J. Infect. Dis. 185, 898-904 (2002).
38. Marcelin, A.G. et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol. 72, 162-165 (2004).
39. Girouard, M., Diallo, K., Marchand, B., McCormick, S. & Gotte, M. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC. J. Biol. Chem. 278, 34403-34410 (2003).
40. White, K.L. et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir. Ther. 11, 155-163 (2006).
41. Parikh, U.M., Zelina, S., Sluis-Cremer, N. & Mellors, J.W. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 21, 1405-1414 (2007).
42. Gu, Z., Fletcher, R.S., Arts, E.J., Wainberg, M.A. & Parniak, M.A. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′, 3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specifc dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269, 28118-28122 (1994).
43. White, K.L. et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profle of HIV-1 K65R RT. AIDS 19, 1751-1760 (2005).
44. Das, K. et al. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J. Mol. Biol. 365, 77-89 (2007).
45. Mansky, L.M. & Bernard, L.C. 3′-Azido-3′-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodefciency virus type 1. J. Virol. 74, 9532-9539 (2000).
46. Das, K. et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75, 4771-4779 (2001).
47. Urban, S., Fischer, K.P. & Tyrrell, D.L. Effcient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism. Proc. Natl. Acad. Sci. USA 98, 4984-4989 (2001).
48. Deval, J., Powdrill, M.H., D'Abramo, C.M., Cellai, L. & Gotte, M. Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 51, 2920-2928 (2007).
49. Acosta-Hoyos, A.J. & Scott, W.A. The role of nucleotide excision by reverse transcriptase in HIV drug resistance. Viruses 2, 372-394 (2010).
50. Kellam, P., Boucher, C.A. & Larder, B.A. Fifth mutation in human immunodefciency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89, 1934-1938 (1992).
51. Deval, J. et al. Mechanistic basis for reduced viral and enzymatic ftness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279, 509-516 (2004).
52. Sluis-Cremer, N., Arion, D., Kaushik, N., Lim, H. & Parniak, M.A. Mutational analysis of Lys65 of HIV-1 reverse transcriptase. Biochem. J. 348, 77-82 (2000).
53. Arion, D. & Parniak, M.A. HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resist. Updat. 2, 91-95 (1999).
54. Yahi, N. et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodefciency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J. Clin. Microbiol. 37, 4099-4106 (1999).
55. Cozzi-Lepri, A. et al. Thymidine analogue mutation profles: factors associated with acquiring specifc profles and their impact on the virological response to therapy. Antivir. Ther. 10, 791-802 (2005).
56. Sarafanos, S.G. et al. Trapping HIV-1 reverse transcriptase before and after translocation on DNA. J. Biol. Chem. 278, 16280-16288 (2003).
57. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
58. Strong, M. et al. Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103, 8060-8065 (2006).
59. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
60. Brünger, A.T. et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921 (1998).